Project Grant R43CK000521

This SBIR Phase I Project Grant award of $298,646, provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a rapid diagnostic test for identifying sepsis-causing pathogens from small blood volumes. The proposed DNA-based technology seeks to comprehensively detect and quantify a wide range of pathogens within a few hours, addressing limitations of current culture-based methods that require larger blood samples and...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...

This Cooperative Agreement award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $1,144,758.00 to Promedix, Inc. to develop an automated electronic measurement device for improving the diagnosis and treatment of sepsis. The project aims to create a novel system that can rapidly and quantifiably assess capillary refill time, a key indicator of sepsis, in order to enable earlier intervention and improve patient outcomes. This Phase...

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 to Resonantia Diagnostics, Inc. to develop a transformative diagnostic platform for rapid identification and antimicrobial susceptibility testing of pathogens. The project aims to achieve three key technical objectives: (1) demonstrate accurate antimicrobial susceptibility testing at very low pathogen loads, (2) validate testing...

This $294,244 Project Grant award, funded by the Department of Health and Human Services (DHHS) Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program, supports research to identify sepsis phenotypes associated with antibiotic-resistant pathogens. The project aims to leverage machine learning techniques, including large language models applied to clinical notes, to augment electronic health record (EHR) data and define...

This $305,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of a clinical decision support system (CDSS) called Sepsis FLO. The CDSS is designed to precisely guide blood volume diagnosis and treatment for sepsis patients. Key activities include: 1) Developing an alpha prototype of the CDSS through user-centered design; 2) Validating three functional...

The National Science Foundation (NSF) awarded a $305,000 SBIR Phase I Project Grant to Giant Biosystems Inc. on March 1, 2025. The project aims to develop a rapid, point-of-care antimicrobial susceptibility testing (AST) kit that can provide results on the same day a sample is taken. This is expected to help physicians utilize the most effective antibiotics sooner, reducing antimicrobial resistance and associated economic burdens. The proposed microfluidic platform is designed to generate...

This $991,832 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel rapid antibiotic susceptibility testing (AST) platform by Astek Diagnostics Inc., a minority-owned small business in Halethorpe, Maryland. The project aims to adapt the company's previously developed urine cartridge technology for use with cerebrospinal fluid and wound effluent specimens, characterize...

This Project Grant award of $750,561 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the SMART-SEPSIS study. The study aims to use electronic health record data and artificial intelligence/machine learning to model individual patient response to sepsis treatment and promote early but reasoned application of the hour-1 sepsis treatment bundle for patients with suspected community-onset lung sepsis. The goal is...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $473,937 Project Grant to The General Hospital Corporation (d/b/a Massachusetts General Hospital) for the project "Novel Point-of-Care Liquid Biopsy for Early Detection of Sepsis-Associated Organ Damage". The project aims to develop a novel circulating cellular biomarker for the early detection and assessment of...